CUSIP No. 15117F500 Page 1 of 6

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 13G**

Under the Securities Exchange Act of 1934

Cellectar Biosciences, Inc.					
			(Nam	ne of Issuer)	
			Common stock	c, par value \$0.00001	
				ass of Securities)	
			15:	117F500	
			(CUS)	IP Number)	
				nber 31, 2020	
			(Date of Event Which Re	equires Filing of this Statement)	
Check the app	ropriate box to designate t	he rule pursua	nt to which this Schedule is filed	d:	
	Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d)				
			for a reporting person's initial the disclosures provided in a pri	filing on this form with respect to the subject class of securities, and for any ior cover page.	subsequent
				ther provisions of the Act (however, see the Notes).	4 ("Act") or
CUSIP No. 15	117F500				Page 2 of 6
1.	Names of Reporting Pe	erson		Sio Capital Management, LLC	
	I.R.S. Identification No Above Persons (entitie only)			20-4586565	
2.	Check the Appropriate if a Member of a Grou			(a)	
3.	SEC Use Only				
4.	Citizenship or Place of Organization			Delaware	
	ares Beneficially	5.	Sole Voting Power		-0-
Owned by Each Reporting Person With <sup>1</sup>		6.	Shared Voting Power		2,331,123
		7.	Sole Dispositive Power		-0-
		8.	Shared Dispositive Pow	ver	2,331,123
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,331,12				
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares				
11.	Percent of Class Represented by Amount in Row (9) 8.69%				

12.	Type of Reporting Person	IA
The owners	ship information reported in this Schedule 13G	LC beneficially owned 2,331,123 shares of Common Stock with shared voting power and shared dispositive power. It is as of December 31, 2020.  Ing as of November 4, 2020, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2020.
CUSIP No.	15117F500	Page <b>3</b> of <b>6</b>
		Schedule 13G
Item 1(a).	Name of Issuer:	
	Cellectar Biosciences, Inc.	
Item 1(b).	Address of Issuer's Principal Execut	ive Offices:
	100 Campus Drive Florham Park, New Jersey 07932	
Item 2(a).	Name of Persons Filing:	
	This Statement is filed on behalf of Sio Capit	tal Management, LLC (the "Reporting Person" or "Sio")
	Sio is a registered investment adviser to certa respective investors, and in such capacity Sio	ain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their o has voting and dispositive power over such shares.
Item 2(b).	Address of Principal Business Office	:
	600 Third Avenue, 2 <sup>nd</sup> Floor New York, New York 10016	
Item 2(c).	Citizenship:	
	Sio is a Delaware limited liability company.	
Item 2(d).	Title of Class of Securities:	
	Common stock, par value \$0.00001	
Item 2(e).	CUSIP Number:	
	15117F500	
CUSIP No.	15117F500	Page <b>4</b> of <b>6</b>
Item 3. If t	his statement is filed pursuant to §§ 240.13c	d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(b) I (c) I	Broker or dealer registered under sect Bank as defined in section 3(a)(6) of t Insurance company as defined in sect Investment company registered under	

- (e) (f) X An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
- An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). (g)
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-(i)
- (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).
- If this statement is filed pursuant to §240.13d-1(c), check this box.

#### Item 4. Ownership.

(a) through (c):

The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference.

#### Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Various advisory clients of the Reporting Person have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Cellectar Biosciences, Inc. in their accounts with the Reporting Person. No such person has such interest relating to more than 5% of the outstanding shares of Common Stock of Cellectar Biosciences, Inc.

CUSIP No. 15117F500 Page **5** of **6** 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of a Group.

Not Applicable.

### Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to herein were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 15117F500 Page 6 of 6

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2021

SIO CAPITAL MANAGEMENT, LLC

Name: Judah Drillick Title: Chief Executive Officer

<sup>&</sup>lt;sup>3</sup> Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.